Brookfield Quarterly Profit Rises, Beating Expectations
By Robb M. Stewart
Brookfield's first-quarter earnings rose with strong fundraising and capital deployment in its asset-management business and a strong investment performance at its wealth-0solutions arm.
Distributable earnings, a measure of cash that can be returned to shareholders, rose to $1.22 billion in the first quarter from $1.16 billion a year earlier. On a per-share basis, distributable earnings rose to 77 cents from 72 cents, beating the 70 cents analysts polled by FactSet were expecting.
Net income climbed to $519 million, or 4 cents a share, from $424 million, or 5 cents a share, although revenue slipped 1.7% to $22.91 billion for the quarter
Toronto-based Brookfield, which in late 2022 spun off a 25% stake in its asset-management business, ended March with a record $150 billion of deployable capital, including roughly $65 billion of cash, financial assets and undrawn credit lines. Brookfield said it arranged about $40 billion of financing across its business over the past few months, including issuing $750 million in 30-year bonds to bolster balance-sheet liquidity.
On Tuesday, Brookfield Asset Management reported $547 million in distributable earnings for the recent quarter, with a 16% fall in revenue to $884 million.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 09, 2024 07:56 ET (11:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks